Analgesics
Antiandrogens
Antihistamines
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchSelect treatment..Select..
Metformin Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta Thermotherapy Meta
Melatonin Meta

 

Endotracheal Application of Ultraviolet A Light in Critically Ill Patients with Severe Acute Respiratory Syndrome Coronavirus 2: A First-in-Human Study

Rezaie et al., Advances in Therapy, doi:10.1007/s12325-021-01830-7, NCT04572399
Jun 2021  
  Post
  Facebook
Share
  Source   PDF  
Small trial of 5 critically ill intubated COVID-19 patients showing significant reductions in endotracheal SARS-CoV-2 viral load with 5 days of narrow-band UVA light therapy delivered via endotracheal tube. Reduction in viral load correlated with clinical improvement based on WHO severity scores at 30 days. No treatment-related adverse events were observed.
Rezaie et al., 26 Jun 2021, prospective, USA, peer-reviewed, mean age 56.6, 10 authors, study period 30 October, 2020 - 28 November, 2020, trial NCT04572399 (history). Contact: ali.rezaie@cshs.org.
This PaperMiscellaneousAll
Endotracheal Application of Ultraviolet A Light in Critically Ill Patients with Severe Acute Respiratory Syndrome Coronavirus 2: A First-in-Human Study
Ali Rezaie, Gil Y Melmed, Gabriela Leite, Ruchi Mathur, Will Takakura, Isabel Pedraza, Michael Lewis, Rekha Murthy, George Chaux, Mark Pimentel
Advances in Therapy, doi:10.1007/s12325-021-01830-7
preclinical experiments show that under specific and monitored conditions, ultraviolet A (UVA) exposure reduces certain bacteria, fungi, and viruses including
Author Contributions. Study concept and design: AR, GYM, RM, MP, GC, IP, ML, RM.Acquisition of data: AR, GYM, WT, GL, GC, IP.Analysis and interpretation of data: AR, GYM, GL, RM, MP, WT, GC.Drafting of the manuscript: AR, GL, GYM, RM, MP.Critical revision of the manuscript for important intellectual content: all authors Compliance with Ethics Guidelines. The trial protocol (ClinicalTrials.gov number NCT04572399) was approved by the institutional review board of Cedars-Sinai, Los Angeles, California, USA, and was overseen by an independent data and safety monitoring board (DSMB). Subjects' legally authorized representatives provided written informed consent. The study was conducted according to the guidelines of the Declaration of Helsinki. Data Availability. All data generated or analyzed during this study are included in this published article or in the supplementary information files. Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in..
References
Alhazzani, Evans, Alshamsi, Surviving sepsis campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update, Crit Care Med, doi:10.1097/CCM.0000000000004899
Datta, Talwar, Lee, A proposed framework and timeline of the spectrum of disease due to SARS-CoV-2 infection: illness beyond acute infection and public health implications, JAMA, doi:10.1001/jama.2020.22717
Fletcher-Sandersjoo, Bartek, Jr, Predictors of intracranial hemorrhage in adult patients on extracorporeal membrane oxygenation: an observational cohort study, J Intensive Care, doi:10.1186/s40560-017-0223-2
Fu, Wang, Zheng, SARS-CoV-2 membrane glycoprotein M antagonizes the MAVSmediated innate antiviral response, Cell Mol Immunol, doi:10.1038/s41423-020-00571-x
Hamet, Pavon, Dalle, Candida spp. airway colonization could promote antibiotic-resistant bacteria selection in patients with suspected ventilator-associated pneumonia, Intensive Care Med, doi:10.1007/s00134-012-2584-2
Leite, Rezaie, Mathur, Barlow, Melmed et al., Ultraviolet-A light increases mitochondrial anti-viral signaling protein in confluent human tracheal cells even at a distance from the light source, bioRxiv, doi:10.1101/2021.05.11.443549
Luyt, Sahnoun, Gautier, Ventilatorassociated pneumonia in patients with SARS-CoV-2-associated acute respiratory distress syndrome requiring ECMO: a retrospective cohort study, Ann Intensive Care, doi:10.1186/s13613-020-00775-4
Metnitz, Moreno, Almeida, SAPS 3-From evaluation of the patient to evaluation of the intensive care unit. Part 1: objectives, methods and cohort description, Intensive Care Med, doi:10.1007/s00134-005-2762-6
Mohanty, Tiwari-Pandey, Pandey, Mitochondria: the indispensable players in innate immunity and guardians of the inflammatory response, J Cell Commun Signal, doi:10.1007/s12079-019-00507-9
Moreno, Metnitz, Almeida, SAPS 3-From evaluation of the patient to evaluation of the intensive care unit. Part 2: development of a prognostic model for hospital mortality at ICU admission, Intensive Care Med, doi:10.1007/s00134-005-2763-5
Pujadas, Chaudhry, Mcbride, SARS-CoV-2 viral load predicts COVID-19 mortality, Lancet Respir Med, doi:10.1016/S2213-2600(20)30354-4
Rezaie, Leite, Melmed, Ultraviolet A light effectively reduces bacteria and viruses including coronavirus, PLoS ONE, doi:10.1371/journal.pone.0236199
Sklar, Sy, Lequier, Kanji, Anticoagulation practices during venovenous extracorporeal membrane oxygenation for respiratory failure. A systematic review, Ann Am Thorac Soc, doi:10.1513/AnnalsATS.201605-364SR
Sungnak, Huang, Becavin, SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes, Nat Med, doi:10.1038/s41591-020-0868-6
Team, Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States, Nat Med, doi:10.1038/s41591-020-0877-5
Vahidy, Drews, Masud, Characteristics and outcomes of COVID-19 patients during initial peak and resurgence in the houston metropolitan area, JAMA, doi:10.1001/jama.2020.15301
Vieyra-Garcia, Wolf, A deep dive into UVbased phototherapy: mechanisms of action and emerging molecular targets in inflammation and cancer, Pharmacol Ther, doi:10.1016/j.pharmthera.2020.107784
Vincent, Moreno, Takala, The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine, Intensive Care Med, doi:10.1007/BF01709751
Winter, Using the Student's t-test with extremely small sample sizes, Pract Assess Res Eval
Wu, Shi, Pan, SARS-CoV-2 ORF9b inhibits RIG-I-MAVS antiviral signaling by interrupting K63-linked ubiquitination of NEMO, Cell Rep, doi:10.1016/j.celrep.2021.108761
Zheng, Yu, Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study, BMJ, doi:10.1136/bmj.m1443
DOI record: { "DOI": "10.1007/s12325-021-01830-7", "ISSN": [ "0741-238X", "1865-8652" ], "URL": "http://dx.doi.org/10.1007/s12325-021-01830-7", "alternative-id": [ "1830" ], "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "10 May 2021" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "15 June 2021" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 3, "value": "26 June 2021" } ], "author": [ { "ORCID": "http://orcid.org/0000-0002-0106-372X", "affiliation": [], "authenticated-orcid": false, "family": "Rezaie", "given": "Ali", "sequence": "first" }, { "affiliation": [], "family": "Melmed", "given": "Gil Y.", "sequence": "additional" }, { "affiliation": [], "family": "Leite", "given": "Gabriela", "sequence": "additional" }, { "affiliation": [], "family": "Mathur", "given": "Ruchi", "sequence": "additional" }, { "affiliation": [], "family": "Takakura", "given": "Will", "sequence": "additional" }, { "affiliation": [], "family": "Pedraza", "given": "Isabel", "sequence": "additional" }, { "affiliation": [], "family": "Lewis", "given": "Michael", "sequence": "additional" }, { "affiliation": [], "family": "Murthy", "given": "Rekha", "sequence": "additional" }, { "affiliation": [], "family": "Chaux", "given": "George", "sequence": "additional" }, { "affiliation": [], "family": "Pimentel", "given": "Mark", "sequence": "additional" } ], "clinical-trial-number": [ { "clinical-trial-number": "nct04572399", "registry": "10.18810/clinical-trials-gov" } ], "container-title": "Advances in Therapy", "container-title-short": "Adv Ther", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2021, 6, 26 ] ], "date-time": "2021-06-26T11:02:55Z", "timestamp": 1624705375000 }, "deposited": { "date-parts": [ [ 2021, 8, 10 ] ], "date-time": "2021-08-10T16:40:20Z", "timestamp": 1628613620000 }, "funder": [ { "name": "Aytu Biosciences" } ], "indexed": { "date-parts": [ [ 2024, 7, 1 ] ], "date-time": "2024-07-01T20:32:20Z", "timestamp": 1719865940361 }, "is-referenced-by-count": 8, "issue": "8", "issued": { "date-parts": [ [ 2021, 6, 26 ] ] }, "journal-issue": { "issue": "8", "published-print": { "date-parts": [ [ 2021, 8 ] ] } }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by-nc/4.0", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2021, 6, 26 ] ], "date-time": "2021-06-26T00:00:00Z", "timestamp": 1624665600000 } }, { "URL": "https://creativecommons.org/licenses/by-nc/4.0", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2021, 6, 26 ] ], "date-time": "2021-06-26T00:00:00Z", "timestamp": 1624665600000 } } ], "link": [ { "URL": "https://link.springer.com/content/pdf/10.1007/s12325-021-01830-7.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/article/10.1007/s12325-021-01830-7/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/content/pdf/10.1007/s12325-021-01830-7.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "page": "4556-4568", "prefix": "10.1007", "published": { "date-parts": [ [ 2021, 6, 26 ] ] }, "published-online": { "date-parts": [ [ 2021, 6, 26 ] ] }, "published-print": { "date-parts": [ [ 2021, 8 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "DOI": "10.1001/jama.2020.15301", "author": "FS Vahidy", "doi-asserted-by": "publisher", "first-page": "998", "issue": "10", "journal-title": "JAMA", "key": "1830_CR1", "unstructured": "Vahidy FS, Drews AL, Masud FN, et al. Characteristics and outcomes of COVID-19 patients during initial peak and resurgence in the houston metropolitan area. JAMA. 2020;324(10):998–1000. https://doi.org/10.1001/jama.2020.15301.", "volume": "324", "year": "2020" }, { "DOI": "10.1097/CCM.0000000000004899", "author": "W Alhazzani", "doi-asserted-by": "publisher", "first-page": "e219", "issue": "3", "journal-title": "Crit Care Med", "key": "1830_CR2", "unstructured": "Alhazzani W, Evans L, Alshamsi F, et al. Surviving sepsis campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update. Crit Care Med. 2021;49(3):e219–34. https://doi.org/10.1097/CCM.0000000000004899.", "volume": "49", "year": "2021" }, { "DOI": "10.1038/s41591-020-0868-6", "author": "W Sungnak", "doi-asserted-by": "publisher", "first-page": "681", "issue": "5", "journal-title": "Nat Med", "key": "1830_CR3", "unstructured": "Sungnak W, Huang N, Becavin C, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26(5):681–7. https://doi.org/10.1038/s41591-020-0868-6.", "volume": "26", "year": "2020" }, { "DOI": "10.1186/s13613-020-00775-4", "author": "CE Luyt", "doi-asserted-by": "publisher", "first-page": "158", "issue": "1", "journal-title": "Ann Intensive Care", "key": "1830_CR4", "unstructured": "Luyt CE, Sahnoun T, Gautier M, et al. Ventilator-associated pneumonia in patients with SARS-CoV-2-associated acute respiratory distress syndrome requiring ECMO: a retrospective cohort study. Ann Intensive Care. 2020;10(1):158. https://doi.org/10.1186/s13613-020-00775-4.", "volume": "10", "year": "2020" }, { "DOI": "10.1001/jama.2020.22717", "author": "SD Datta", "doi-asserted-by": "publisher", "first-page": "2251", "issue": "22", "journal-title": "JAMA", "key": "1830_CR5", "unstructured": "Datta SD, Talwar A, Lee JT. A proposed framework and timeline of the spectrum of disease due to SARS-CoV-2 infection: illness beyond acute infection and public health implications. JAMA. 2020;324(22):2251–2. https://doi.org/10.1001/jama.2020.22717.", "volume": "324", "year": "2020" }, { "DOI": "10.1038/s41591-020-0877-5", "author": "Covid-Investigation Team", "doi-asserted-by": "publisher", "first-page": "861", "issue": "6", "journal-title": "Nat Med", "key": "1830_CR6", "unstructured": "Covid-Investigation Team. Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States. Nat Med. 2020;26(6):861–8. https://doi.org/10.1038/s41591-020-0877-5.", "volume": "26", "year": "2020" }, { "DOI": "10.1038/s41423-020-00571-x", "author": "YZ Fu", "doi-asserted-by": "publisher", "journal-title": "Cell Mol Immunol", "key": "1830_CR7", "unstructured": "Fu YZ, Wang SY, Zheng ZQ, et al. SARS-CoV-2 membrane glycoprotein M antagonizes the MAVS-mediated innate antiviral response. Cell Mol Immunol. 2020. https://doi.org/10.1038/s41423-020-00571-x.", "year": "2020" }, { "DOI": "10.1007/s12079-019-00507-9", "author": "A Mohanty", "doi-asserted-by": "publisher", "first-page": "303", "issue": "3", "journal-title": "J Cell Commun Signal", "key": "1830_CR8", "unstructured": "Mohanty A, Tiwari-Pandey R, Pandey NR. Mitochondria: the indispensable players in innate immunity and guardians of the inflammatory response. J Cell Commun Signal. 2019;13(3):303–18. https://doi.org/10.1007/s12079-019-00507-9.", "volume": "13", "year": "2019" }, { "DOI": "10.1016/j.celrep.2021.108761", "author": "J Wu", "doi-asserted-by": "publisher", "first-page": "108761", "issue": "7", "journal-title": "Cell Rep", "key": "1830_CR9", "unstructured": "Wu J, Shi Y, Pan X, et al. SARS-CoV-2 ORF9b inhibits RIG-I-MAVS antiviral signaling by interrupting K63-linked ubiquitination of NEMO. Cell Rep. 2021;34(7):108761. https://doi.org/10.1016/j.celrep.2021.108761.", "volume": "34", "year": "2021" }, { "DOI": "10.1016/j.pharmthera.2020.107784", "author": "PA Vieyra-Garcia", "doi-asserted-by": "publisher", "journal-title": "Pharmacol Ther", "key": "1830_CR10", "unstructured": "Vieyra-Garcia PA, Wolf P. A deep dive into UV-based phototherapy: mechanisms of action and emerging molecular targets in inflammation and cancer. Pharmacol Ther. 2020. https://doi.org/10.1016/j.pharmthera.2020.107784.", "year": "2020" }, { "DOI": "10.1371/journal.pone.0236199", "author": "A Rezaie", "doi-asserted-by": "publisher", "first-page": "e0236199", "issue": "7", "journal-title": "PLoS ONE", "key": "1830_CR11", "unstructured": "Rezaie A, Leite GGS, Melmed GY, et al. Ultraviolet A light effectively reduces bacteria and viruses including coronavirus. PLoS ONE. 2020;15(7):e0236199. https://doi.org/10.1371/journal.pone.0236199.", "volume": "15", "year": "2020" }, { "DOI": "10.1101/2021.05.11.443549", "author": "G Leite", "doi-asserted-by": "publisher", "journal-title": "bioRxiv", "key": "1830_CR12", "unstructured": "Leite G, Rezaie A, Mathur R, Barlow G, Melmed GY, Pimentel M. Ultraviolet-A light increases mitochondrial anti-viral signaling protein in confluent human tracheal cells even at a distance from the light source. bioRxiv. 2021. https://doi.org/10.1101/2021.05.11.443549.", "year": "2021" }, { "DOI": "10.1016/S2213-2600(20)30354-4", "author": "E Pujadas", "doi-asserted-by": "publisher", "first-page": "e70", "issue": "9", "journal-title": "Lancet Respir Med", "key": "1830_CR13", "unstructured": "Pujadas E, Chaudhry F, McBride R, et al. SARS-CoV-2 viral load predicts COVID-19 mortality. Lancet Respir Med. 2020;8(9):e70. https://doi.org/10.1016/S2213-2600(20)30354-4.", "volume": "8", "year": "2020" }, { "DOI": "10.1136/bmj.m1443", "author": "S Zheng", "doi-asserted-by": "publisher", "first-page": "m1443", "journal-title": "BMJ", "key": "1830_CR14", "unstructured": "Zheng S, Fan J, Yu F, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. BMJ. 2020;369:m1443. https://doi.org/10.1136/bmj.m1443.", "volume": "369", "year": "2020" }, { "DOI": "10.1016/S1473-3099(20)30483-7", "author": "WHO Working Group on the Clinical Characterisation and Management of Covid-19 infection", "doi-asserted-by": "publisher", "first-page": "e192", "issue": "8", "journal-title": "Lancet Infect Dis", "key": "1830_CR15", "unstructured": "WHO Working Group on the Clinical Characterisation and Management of Covid-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192–7. https://doi.org/10.1016/S1473-3099(20)30483-7.", "volume": "20", "year": "2020" }, { "DOI": "10.1007/BF01709751", "author": "JL Vincent", "doi-asserted-by": "publisher", "first-page": "707", "issue": "7", "journal-title": "Intensive Care Med", "key": "1830_CR16", "unstructured": "Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707–10. https://doi.org/10.1007/BF01709751.", "volume": "22", "year": "1996" }, { "DOI": "10.1007/s00134-005-2762-6", "author": "PG Metnitz", "doi-asserted-by": "publisher", "first-page": "1336", "issue": "10", "journal-title": "Intensive Care Med", "key": "1830_CR17", "unstructured": "Metnitz PG, Moreno RP, Almeida E, et al. SAPS 3–From evaluation of the patient to evaluation of the intensive care unit. Part 1: objectives, methods and cohort description. Intensive Care Med. 2005;31(10):1336–44. https://doi.org/10.1007/s00134-005-2762-6.", "volume": "31", "year": "2005" }, { "DOI": "10.1007/s00134-005-2763-5", "author": "RP Moreno", "doi-asserted-by": "publisher", "first-page": "1345", "issue": "10", "journal-title": "Intensive Care Med", "key": "1830_CR18", "unstructured": "Moreno RP, Metnitz PG, Almeida E, et al. SAPS 3–From evaluation of the patient to evaluation of the intensive care unit. Part 2: development of a prognostic model for hospital mortality at ICU admission. Intensive Care Med. 2005;31(10):1345–55. https://doi.org/10.1007/s00134-005-2763-5.", "volume": "31", "year": "2005" }, { "author": "JCF De Winter", "first-page": "10", "issue": "1", "journal-title": "Pract Assess Res Eval", "key": "1830_CR19", "unstructured": "De Winter JCF. Using the Student’s t-test with extremely small sample sizes. Pract Assess Res Eval. 2013;18(1):10.", "volume": "18", "year": "2013" }, { "DOI": "10.1007/s00134-012-2584-2", "author": "M Hamet", "doi-asserted-by": "publisher", "first-page": "1272", "issue": "8", "journal-title": "Intensive Care Med", "key": "1830_CR20", "unstructured": "Hamet M, Pavon A, Dalle F, et al. Candida spp. airway colonization could promote antibiotic-resistant bacteria selection in patients with suspected ventilator-associated pneumonia. Intensive Care Med. 2012;38(8):1272–9. https://doi.org/10.1007/s00134-012-2584-2.", "volume": "38", "year": "2012" }, { "DOI": "10.1513/AnnalsATS.201605-364SR", "author": "MC Sklar", "doi-asserted-by": "publisher", "first-page": "2242", "issue": "12", "journal-title": "Ann Am Thorac Soc", "key": "1830_CR21", "unstructured": "Sklar MC, Sy E, Lequier L, Fan E, Kanji HD. Anticoagulation practices during venovenous extracorporeal membrane oxygenation for respiratory failure. A systematic review. Ann Am Thorac Soc. 2016;13(12):2242–50. https://doi.org/10.1513/AnnalsATS.201605-364SR.", "volume": "13", "year": "2016" }, { "DOI": "10.1186/s40560-017-0223-2", "author": "A Fletcher-Sandersjoo", "doi-asserted-by": "publisher", "first-page": "27", "journal-title": "J Intensive Care", "key": "1830_CR22", "unstructured": "Fletcher-Sandersjoo A, Bartek J Jr, et al. Predictors of intracranial hemorrhage in adult patients on extracorporeal membrane oxygenation: an observational cohort study. J Intensive Care. 2017;5:27. https://doi.org/10.1186/s40560-017-0223-2.", "volume": "5", "year": "2017" } ], "reference-count": 22, "references-count": 22, "relation": { "has-preprint": [ { "asserted-by": "object", "id": "10.1101/2021.03.05.21252997", "id-type": "doi" } ] }, "resource": { "primary": { "URL": "https://link.springer.com/10.1007/s12325-021-01830-7" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Endotracheal Application of Ultraviolet A Light in Critically Ill Patients with Severe Acute Respiratory Syndrome Coronavirus 2: A First-in-Human Study", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "volume": "38" }
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit